لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Rücker FG; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Corbacioglu A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Krzykalla J; Division of Biostatistics German Cancer Research Center Heidelberg Germany., Cocciardi S; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Lengerke C; Medical Clinic, Department of Hematology, Oncology, Clinical Immunology and Rheumatology University Hospital Tübingen Tübingen Germany., Germing U; Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Düsseldorf Germany., Wulf G; Department of Hematology and Medical Oncology University Medical Center Göttingen Göttingen Germany., Samra MA; Department of Internal Medicine IV University Hospital of Gießen Gießen Germany., Teichmann LL; Department of Medicine and Polyclinic III Bonn University Hospital Bonn Germany., Lübbert M; Department of Hematology, Oncology and Stem Cell Transplantation University of Freiburg Medical Center Freiburg Germany., Kühn MWM; Department of Hematology and Oncology University Medical Center Mainz Mainz Germany., Bentz M; Department of Internal Medicine III Hospital of Karlsruhe Karlsruhe Germany., Westermann J; Department of Hematology, Oncology and Tumor Immunology Charité University Medicine Berlin Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology Charité University Medicine Berlin Germany., Gaidzik VI; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Meid A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Aicher S; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Stegelmann F; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Weber D; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Schrade A; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Thol F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany., Benner A; Division of Biostatistics German Cancer Research Center Heidelberg Germany., Döhner H; Department of Internal Medicine III University Hospital of Ulm Ulm Germany., Döhner K; Department of Internal Medicine III University Hospital of Ulm Ulm Germany.

مؤلفون مشاركون: German‐Austrian Acute Myeloid Leukemia Study Group (AMLSG)

المصدر: HemaSphere [Hemasphere] 2024 Jul 15; Vol. 8 (7), pp. e123. Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

المؤلفون: Klever MK; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany., Sträng E; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Hetzel S; Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany., Jungnitsch J; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany., Dolnik A; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Schöpflin R; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany., Schrezenmeier JF; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Schick F; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Blau O; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Westermann J; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Xia Z; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany., Spielmann M; Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institut für Humangenetik Lübeck, Universität zu Lübeck, Lübeck, Germany., Meissner A; Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany., Melo US; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany., Mundlos S; RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany.; Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany., Bullinger L; Division of Hematology, Oncology, and Cancer Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

المصدر: Blood advances [Blood Adv] 2023 Nov 14; Vol. 7 (21), pp. 6520-6531.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/therapy, Humans ; Abnormal Karyotype ; Chromosome Aberrations ; Mutation ; Genomics ; Ubiquitin-Specific Peptidase 7/genetics

المؤلفون: Grasedieck S; University of British Columbia, Dept. of Microbiology and Immunology, MSL Building, 2125 East Mall Vancouver, BC. sgrasedieck@bcgsc.ca., Cabantog A; Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC., MacPhee L; Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC., Im J; Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC., Ruess C; Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm., Demir B; Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm., Sperb N; Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm., Rücker FG; Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm., Döhner K; Ulm University Hospital, Dept of Internal Medicine III, Albert-Einstein-Allee 23, Ulm., Herold T; Department of Medicine III, University Hospital, LMU Munich, Marchioninistr. 15, Munich., Pollack JR; Department of Pathology, Stanford University School of Medicine, Stanford, CA., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin., Rouhi A; Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC., Kuchenbauer F; Terry Fox Laboratory, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC. fkuchenbauer@bccrc.ca.

المصدر: Haematologica [Haematologica] 2022 Aug 01; Vol. 107 (8), pp. 1758-1772. Date of Electronic Publication: 2022 Aug 01.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/pathology , Nuclear Receptor Interacting Protein 1*/genetics , Nuclear Receptor Interacting Protein 1*/metabolism, Chromosome Aberrations ; Chromosomes/metabolism ; Humans ; MDS1 and EVI1 Complex Locus Protein/genetics ; Receptors, Retinoic Acid/genetics

المؤلفون: Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Du L; Novartis Pharmaceuticals, Cambridge, MA, USA., Luck TJ; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Gathmann I; Novartis Pharmaceuticals, Basel, Switzerland., Voso MT; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Amadori S; Department of Biomedicine and Prevention, Università di Roma 'Tor Vergata', Rome, Italy., Prior TW; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Brandwein JM; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Appelbaum FR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Medeiros BC; Division of Hematology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA, USA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Savoie L; University of Calgary, Calgary, AB, Canada., Sierra J; Hematology Department, Hospital de la Santa Creu i Sant Pau and Jose Carreras Leukemia Research Institute, Autonomus University of Barcelona, Barcelona, Spain., Pallaud C; Novartis Pharmaceuticals, Basel, Switzerland., Sanz MA; Hospital Universitario la Fe, Hematology Department, Department of Medicine, University of Valencia, Valencia, Spain., Jansen JH; Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, The Netherlands., Niederwieser D; Hematology and Oncology, University of Leipzig, Leipzig, Germany., Fischer T; Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Magdeburg, Magdeburg, Germany., Ehninger G; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité University, Berlin, Germany., Larson RA; Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA., Bloomfield CD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Thiede C; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. konstanze.doehner@uniklinik-ulm.de.

المصدر: Leukemia [Leukemia] 2022 Jan; Vol. 36 (1), pp. 90-99. Date of Electronic Publication: 2021 Jul 28.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Mutagenesis, Insertional* , Tandem Repeat Sequences*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biomarkers, Tumor/*genetics , Leukemia, Myeloid, Acute/*pathology , fms-Like Tyrosine Kinase 3/*genetics, Combined Modality Therapy ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate ; Transplantation, Homologous

المؤلفون: Schmalbrock LK; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany., Dolnik A; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Cocciardi S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Sträng E; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Theis F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Blätte TJ; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Herzig J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Skambraks S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Gaidzik VI; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Paschka P; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Fiedler W; Section of Pneumology, Department of Oncology, Hematology and Bone Marrow Transplantation, Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Salih HR; Department of Hematology and Oncology, Eberhard Karls University Tübingen, Tübingen, Germany., Wulf G; Department of Hematology and Oncology, Georg-August-University Göttingen, Göttingen, Germany., Schroeder T; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany., Lübbert M; Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany., Schlenk RF; National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Larson RA; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Stunnenberg HG; Department of Molecular Biology, Faculty of Science, Radboud University, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Minucci S; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and., Bloomfield CD; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Bullinger L; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany.; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

المصدر: Blood [Blood] 2021 Jun 03; Vol. 137 (22), pp. 3093-3104.

نوع المنشور: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/metabolism , Mutation* , fms-Like Tyrosine Kinase 3*/genetics , fms-Like Tyrosine Kinase 3*/metabolism, Clonal Evolution/*drug effects , Staurosporine/*analogs & derivatives, Adolescent ; Adult ; Aged ; Clonal Evolution/genetics ; Female ; Humans ; Male ; Middle Aged ; Staurosporine/administration & dosage ; Tandem Repeat Sequences ; Exome Sequencing

المؤلفون: Kapp-Schwoerer S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Weber D; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Corbacioglu A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Gaidzik VI; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Paschka P; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Krönke J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Theis F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Teleanu MV; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Herzig J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Kubanek L; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Schrade A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Göhring G; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Fiedler W; Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Kindler T; Department of Hematology, Medical Oncology, and Pneumology, University Cancer Center Mainz, Mainz, Germany., Schroeder T; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany., Mayer KT; Department of Hematology and Oncology, University Hospital Bonn, Bonn, Germany., Lübbert M; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Wattad M; Department of Hematology, Oncology and Stem Cell Transplantation, Kliniken Essen Süd, Essen, Germany., Götze KS; III. Department of Medicine, Hematology, and Medical Oncology, Technical University of Munich, Munich, Germany., Horst HA; Department of Internal Medicine II, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany., Koller E; III. Department of Medicine, Hematology, and Medical Oncology, Hanuschkrankenhaus Wien, Vienna, Austria., Wulf G; Department of Hematology and Oncology, Georg-August-University Göttingen, Göttingen, Germany., Schleicher J; Department of Hematology and Oncology, Katharinenhospital Stuttgart, Stuttgart, Germany., Bentz M; Department of Internal Medicine III, Municipal Hospital of Karlsruhe, Karlsruhe, Germany., Krauter J; Department of Internal Medicine III, Municipal Hospital of Braunschweig, Braunschweig, Germany., Bullinger L; Department of Hematology, Oncology, and Tumorimmunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Schlenk RF; Nationales Centrum für Tumorerkrankungen Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; and., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

المصدر: Blood [Blood] 2020 Dec 24; Vol. 136 (26), pp. 3041-3050.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/mortality , Mutation*, Gemtuzumab/*administration & dosage , Neoplasm Proteins/*genetics , Nuclear Proteins/*genetics, Adult ; Aged ; Aged, 80 and over ; Bone Marrow ; Disease-Free Survival ; Female ; Gemtuzumab/adverse effects ; Humans ; Male ; Middle Aged ; Neoplasm, Residual ; Nucleophosmin ; Prospective Studies ; Recurrence ; Risk Factors ; Survival Rate

المؤلفون: Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Terzer T; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Sträng E; Department of Hematology, Oncology, Tumor Immunology, Charité University Medicine, Berlin, Germany., Dolnik A; Department of Hematology, Oncology, Tumor Immunology, Charité University Medicine, Berlin, Germany., Cocciardi S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Corbacioglu A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Herzig J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Weber D; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Schrade A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Götze K; Department of Internal Medicine III, University Hospital Klinikum Rechts der Isar, Munich, Germany., Schröder T; Department of Hematology, Oncology, and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany., Lübbert M; Department of Internal Medicine I, Faculty of Medicine, University Hospital of Freiburg, Freiburg, Germany., Wellnitz D; Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany., Koller E; Department of Internal Medicine III, Hanuschkrankenhaus Wien, Wien, Austria., Schlenk RF; National Center of Tumor Diseases-Trial Center, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; and., Gaidzik VI; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Paschka P; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Bullinger L; Department of Hematology, Oncology, Tumor Immunology, Charité University Medicine, Berlin, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

المصدر: Blood advances [Blood Adv] 2020 Dec 22; Vol. 4 (24), pp. 6342-6352.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Core Binding Factors*/genetics , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/genetics, Adult ; Genomics ; Humans ; Mutation ; Prognosis